Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Liedtke

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 15, 2009
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancerC Liedtke, K Broglio, S Moulder, et al.
Clinical & Experimental Metastasis|October 17, 2018
Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST)C Liedtke, Hans-Christian Kolberg, L Kerschke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2016
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc TrialO Gluz, C Liedtke, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxelU A Nitz, O Gluz, M Christgen, et al.
British Journal of Cancer|August 16, 2012
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trialI Witzel, S Loibl, G von Minckwitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2014
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapyJ L Lindner, S Loibl, C Denkert, et al.
Geburtshilfe Und Frauenheilkunde|July 14, 2015
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)M Untch, N Harbeck, J Huober, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 15, 2009
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancerC Liedtke, K Broglio, S Moulder, et al.
Clinical & Experimental Metastasis|October 17, 2018
Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST)C Liedtke, Hans-Christian Kolberg, L Kerschke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2016
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc TrialO Gluz, C Liedtke, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxelU A Nitz, O Gluz, M Christgen, et al.
British Journal of Cancer|August 16, 2012
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trialI Witzel, S Loibl, G von Minckwitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2014
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapyJ L Lindner, S Loibl, C Denkert, et al.
Geburtshilfe Und Frauenheilkunde|July 14, 2015
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)M Untch, N Harbeck, J Huober, et al.
Pageof 3